Bortezomib Pharmacogenetic Biomarkers for the Treatment of Multiple Myeloma: Review and Future Perspectives.
bortezomib
efficacy
multiple myeloma
pharmacogenetic biomarkers
toxicity
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
20 Apr 2023
20 Apr 2023
Historique:
received:
27
03
2023
revised:
14
04
2023
accepted:
19
04
2023
medline:
28
4
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
epublish
Résumé
Multiple myeloma (MM) is a hematological neoplasm for which different chemotherapy treatments are used with several drugs in combination. One of the most frequently used drugs for the treatment of MM is the proteasome inhibitor bortezomib. Patients treated with bortezomib are at increased risk for thrombocytopenia, neutropenia, gastrointestinal toxicities, peripheral neuropathy, infection, and fatigue. This drug is almost entirely metabolized by cytochrome CYP450 isoenzymes and transported by the efflux pump P-glycoprotein. Genes encoding both enzymes and transporters involved in the bortezomib pharmacokinetic pathway are highly polymorphic. The response to bortezomib and the incidence of adverse drug reactions (ADRs) vary among patients, which could be due to interindividual variations in these possible pharmacogenetic biomarkers. In this review, we compiled all pharmacogenetic information relevant to the treatment of MM with bortezomib. In addition, we discuss possible future perspectives and the analysis of potential pharmacogenetic markers that could influence the incidence of ADR and the toxicity of bortezomib. It would be a milestone in the field of targeted therapy for MM to relate potential biomarkers to the various effects of bortezomib on patients.
Identifiants
pubmed: 37109081
pii: jpm13040695
doi: 10.3390/jpm13040695
pmc: PMC10145990
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Références
Adv Drug Deliv Rev. 2002 Nov 18;54(10):1271-94
pubmed: 12406645
Toxics. 2015 Jul 27;3(3):294-303
pubmed: 29051465
Neurobiol Dis. 2016 Apr;88:118-24
pubmed: 26792401
Drug Metab Dispos. 1999 Jul;27(7):804-9
pubmed: 10383924
Cell Cycle. 2014;13(4):612-21
pubmed: 24335344
J Pers Med. 2022 Feb 28;12(3):
pubmed: 35330374
Invest New Drugs. 2016 Apr;34(2):216-24
pubmed: 26924128
Curr Drug Targets. 2018;19(1):38-54
pubmed: 28124606
Cancer Metastasis Rev. 2017 Dec;36(4):561-584
pubmed: 29196868
Oncol Lett. 2015 Aug;10(2):1171-1175
pubmed: 26622646
Front Immunol. 2019 May 21;10:1121
pubmed: 31231360
Annu Rev Med. 2006;57:119-37
pubmed: 16409140
Nature. 2012 Jan 22;482(7383):116-9
pubmed: 22266943
Expert Opin Drug Saf. 2018 Sep;17(9):953-962
pubmed: 30118610
J Pharmacol Exp Ther. 2001 Dec;299(3):825-31
pubmed: 11714865
Clin Lymphoma Myeloma. 2009 Aug;9(4):278-88
pubmed: 19717377
Anticancer Drugs. 2017 Jul;28(6):660-668
pubmed: 28430745
Pharmgenomics Pers Med. 2016 Apr 27;9:47-58
pubmed: 27175090
Pharmacogenet Genomics. 2007 Feb;17(2):93-101
pubmed: 17301689
Pharmacol Ther. 2013 Apr;138(1):103-41
pubmed: 23333322
Curr Top Med Chem. 2013;13(12):1364-84
pubmed: 23688130
Dtsch Arztebl Int. 2016 Jul 11;113(27-28):470-6
pubmed: 27476706
Clin Pharmacol Ther. 2021 Feb;109(2):352-366
pubmed: 32602114
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
JAMA Oncol. 2018 Mar 08;4(3):e174519
pubmed: 29285538
Rev Clin Esp. 2008 Apr;208(4):187-92
pubmed: 18381003
Biomedicines. 2020 Apr 22;8(4):
pubmed: 32331352
Br J Clin Pharmacol. 1996 Sep;42(3):387-9
pubmed: 8877031
Eur J Haematol. 2022 Nov;109(5):425-440
pubmed: 35880395
Mol Pharmacol. 1997 Dec;52(6):1034-40
pubmed: 9415713
Nat Genet. 2001 Apr;27(4):383-91
pubmed: 11279519
Clin Pharmacol Ther. 2022 Nov;112(5):959-967
pubmed: 35034351
Semin Cancer Biol. 1997 Jun;8(3):161-70
pubmed: 9441946
Clin Pharmacokinet. 2011 Dec 1;50(12):781-91
pubmed: 22087865
Leukemia. 2018 Feb;32(2):391-401
pubmed: 28676669
Clin Ther. 2009;31 Pt 2:2444-58
pubmed: 20110052
Clin Pharmacokinet. 2019 Feb;58(2):157-168
pubmed: 29802543
Int J Mol Sci. 2020 Jan 17;21(2):
pubmed: 31963461
Clin Pharmacol Ther. 2012 Oct;92(4):414-7
pubmed: 22992668
Drug Metab Dispos. 2002 Aug;30(8):883-91
pubmed: 12124305
Pharmacogenomics J. 2015 Jun;15(3):288-92
pubmed: 25348618
Clin Pharmacol Ther. 2021 Sep;110(3):662-676
pubmed: 34109627
In Vivo. 2007 Mar-Apr;21(2):273-8
pubmed: 17436576
N Engl J Med. 2018 Aug 2;379(5):485-487
pubmed: 30067934
Mol Pharm. 2018 Nov 5;15(11):5124-5134
pubmed: 30247919
Drug Metab Dispos. 2001 Mar;29(3):268-73
pubmed: 11181494
Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):447-460
pubmed: 29620484
Clin Pharmacokinet. 2009;48(3):199-209
pubmed: 19385713
Clin Pharmacol Ther. 2014 Mar;95(3):258-61
pubmed: 24196843
Pharmacol Res. 2021 May;167:105537
pubmed: 33684510
Drug Metab Dispos. 2005 Nov;33(11):1723-8
pubmed: 16103134
Acta Med Acad. 2019 Apr;48(1):57-67
pubmed: 31264433
Drug Metab Dispos. 2004 Dec;32(12):1434-45
pubmed: 15383492
Int J Mol Sci. 2021 Jan 17;22(2):
pubmed: 33477371
Clin Med (Lond). 2019 Jan;19(1):58-60
pubmed: 30651246
Med Sci (Basel). 2021 Jan 20;9(1):
pubmed: 33498356
J Clin Pharmacol. 2018 Feb;58(2):180-192
pubmed: 28800141
Clin Pharmacol Ther. 2022 Dec;112(6):1159-1171
pubmed: 35202484
J Clin Epidemiol. 2009 Oct;62(10):1006-12
pubmed: 19631508